All Comparisons
Tirzepatide vs Eloralintide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Tirzepatide: AEloralintide: C
| Attribute | Tirzepatide | Eloralintide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Weight Loss & Metabolic |
| Evidence Rating | A — FDA Approved | C — Phase II Clinical Trials |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Phase II clinical trials by Eli Lilly. Active development as of 2025. |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety ... | Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling. Amylin is normally co-secreted with insulin from pancreatic beta cells and acts on brain areas controlling appetite. |
| Half-Life | ~5 days (116 hours) | — |
| Bioavailability | ~80% SC | — |
| Molecular Weight | ~4813.5 g/mol | — |
| WADA Status | Not Prohibited | — |
| Research Half-Life | ~5 days (116 hours) | — |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved: Mounjaro (T2D, adults and children 10+) and Zepbound (obesity/overweight with comorbidities, severe OSA including new sleep apnea approval). Compounding fully prohibited for 503B facilities. Prescription only. | Investigational New Drug (IND). Phase II trials ongoing. Not FDA-approved. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Tirzepatide | Eloralintide |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2023788-19-2 | N/A |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | N/A |
| Available Formats | 10mg, 30mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.